The a Sell rating for TEVA is based on the Portfolio Grader stock evaluator. The system for investing incorporated in this analytical tool evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is one of the 657 companies in the GICS Health Technology sector, and a member of the 15 company Pharmaceuticals: Generic GICS industry group within this sector. The market value of TEVA is $21.0 billion which places it in the upper half of its industry group. The current Portfolio Grader ranking for TEVA puts it 13 among the 15 companies in this industry group, a spot that is well below-average; squarely in the bottom quartile of the sector with a ranking of 571 among the 657 companies in the sector, and number 4,037 in the nearly 5,000 company Portfolio Grader universe.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is classified as a member of the 15 company Pharmaceuticals: Generic GICS industry group, which is part of the 656 company GICS Health Technology sector. TEVA's market value is $19.5 billion which places it in the upper half of its industry group. The stock's current Portfolio Grader ranking places it 12 among the 15 companies in this industry group, a spot that is well below-average; squarely in the bottom quartile of the sector with a ranking of 571 among the 656 companies in the sector, and number 4,066 in the nearly 5,000 company Portfolio Grader universe.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is one of 134 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 779 company GICS Health Care sector. The market value of TEVA is $19.3 billion which falls in the top quarter of its industry group. The current Portfolio Grader ranking for TEVA puts it 117 among the 134 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 680 among the 779 companies in the sector, and number 4,039 in the nearly 5,000 company Portfolio Grader universe.

With a $19.1 billion market value, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) ranks in the top quarter of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the vantage point of investment attractiveness, the stock's current Portfolio Grader ranking places it 111 among the 134 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 671 among the 781 companies in the sector, and number 4,040 in the nearly 5,000 company Portfolio Grader universe.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is a $16.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the current Portfolio Grader ranking for TEVA puts it 128 among the 135 companies in this industry group, a spot that is well below-average. TEVA is ranked squarely in the bottom quartile of the sector with a ranking of 745 among the 782 companies in the sector and number 4,422 in the 5000 company Portfolio Grader company universe.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is a member of the 135 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. TEVA's market value is $16.3 billion which places it in the top 25% of its industry group. The current Portfolio Grader ranking for TEVA puts it 128 among the 135 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 745 among the 782 companies in the sector, and number 4,422 in the nearly 5,000 company Portfolio Grader universe.